Nonalcoholic steatohepatitis

Slides:



Advertisements
Similar presentations
Intracellular Accumulations Fatty Change (Steatosis): Fatty Change (Steatosis): Abnormal accumulation of triglycerides within parenchymal cells seen in.
Advertisements

 Fatty liver disease can range from fatty liver alone (steatosis) to fatty liver associated with inflammation (steatohepatitis). This condition can occur.
Samir Parekh, Frank A. Anania  Gastroenterology 
Nutritional therapy for nonalcoholic fatty liver disease
Oxidants and antioxidants in alcohol-induced liver disease
In the name of GOD.
Cellular and Molecular Mechanisms of Liver Injury
Drug-induced liver injury part II
Volume 148, Issue 4, Pages (April 2015)
From Fat to Inflammation
Toxic responses of the liver
Lipids in Liver Disease: Looking Beyond Steatosis
Pathways of liver injury in alcoholic liver disease
The inflammasome in liver disease
Obesity, inflammation, and liver cancer
Recent insights on the mechanisms of liver preconditioning
Gianluca Tell, Carlo Vascotto, Claudio Tiribelli  Journal of Hepatology 
Oxidants and antioxidants in alcohol-induced liver disease
Volume 47, Issue 1, Pages (July 2007)
Cellular and Molecular Mechanisms of Liver Injury
Leptin, obesity, and liver disease
Volume 120, Issue 6, Pages (May 2001)
Samir Parekh, Frank A. Anania  Gastroenterology 
Volume 133, Issue 2, Pages (August 2007)
Figure 3 ER stress and hepatic steatosis: a vicious cycle
Roles for Chemokines in Liver Disease
Allogeneic hematopoietic cell transplant in HCV-infected patients
Senescence: Not Just for Tumor Suppression
Mechanisms of Hepatic Fibrogenesis
Volume 55, Issue 4, Pages (October 2011)
Volume 123, Issue 1, Pages (July 2002)
Targeting the FXR Nuclear Receptor to Treat Liver Disease
Volume 150, Issue 4, Pages (April 2016)
Frank J. Gonzalez, Changtao Jiang, Andrew D. Patterson 
Signalling pathways in alcohol-induced liver inflammation
Long-Term Outcomes of Nonalcoholic Fatty Liver Disease: From Nonalcoholic Steatohepatitis to Nonalcoholic Steatofibrosis  Zobair M. Younossi  Clinical.
Sugar, Sugar Not So Sweet for the Liver
Volume 62, Issue 1, Pages (January 2015)
Gaps in Knowledge and Research Priorities for Alcoholic Hepatitis
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Mechanisms of iron hepatotoxicity
The lymphoid liver: Considerations on pathways to autoimmune injury
Volume 146, Issue 5, Pages (May 2014)
Michael Charlton  Clinical Gastroenterology and Hepatology 
Pathways of liver injury in alcoholic liver disease
Obesity, Inflammation, and Insulin Resistance
Volume 134, Issue 4, Pages (April 2008)
Wilson Disease Mayo Clinic Proceedings
“De-liver-ance” From CB1: A Way to Counteract Insulin Resistance?
Volume 69, Issue 4, Pages (October 2018)
Cannabinoid signaling and liver therapeutics
Herbert Tilg, Gökhan S. Hotamisligil  Gastroenterology 
Claire Z. Larter, Geoffrey C. Farrell  Journal of Hepatology 
AGA technical review on nonalcoholic fatty liver disease
NASH animal models: Are we there yet?
Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease  Francesco S. Facchini, Nancy.
Volume 44, Issue 5, Pages (May 2006)
Volume 125, Issue 2, Pages (August 2003)
Lipids in Liver Disease: Looking Beyond Steatosis
Volume 142, Issue 4, Pages e6 (April 2012)
Volume 148, Issue 2, Pages (February 2015)
Autophagy in liver diseases: Time for translation?
Silvia Affò, Ramón Bataller  Journal of Hepatology 
Adel Hammoutene, Pierre-Emmanuel Rautou  Journal of Hepatology 
Toxic responses of the liver
Nathalie Ganne-Carrié, Pierre Nahon  Journal of Hepatology 
Shih-Yen Weng, Detlef Schuppan  Journal of Hepatology 
Sander Lefere, Frank Tacke  JHEP Reports 
Volume 120, Issue 4, Pages (March 2001)
Volume 135, Issue 6, Pages (December 2008)
Presentation transcript:

Nonalcoholic steatohepatitis Andrea E. Reid  Gastroenterology  Volume 121, Issue 3, Pages 710-723 (September 2001) DOI: 10.1053/gast.2001.27126 Copyright © 2001 American Gastroenterological Association Terms and Conditions

Fig. 1 The pathogenesis of NASH is poorly understood. Obesity, type 2 diabetes mellitus, hyperinsulinemia, increased triglyceride levels, and certain drugs, toxins, and medical conditions can lead to increased serum fatty acids, which are then presented to the liver. Steatosis occurs when the supply of fatty acids in the liver exceeds that needed for triglyceride synthesis, mitochondrial oxidation, and phospholipid and cholesterol ester synthesis. After steatosis occurs, inflammation and fibrosis characteristic of NASH are probably stimulated by multiple factors. Increased expression of CYP2E1 may cause production of free oxygen radicals capable of inducing lipid peroxidation of hepatocyte membrane. Alterations in mitochondrial energy homeostasis may also contribute to hepatocellular injury. Hepatic iron overload, possibly associated with HFE gene mutations in some patients, may contribute to lipid peroxidation. Lipid peroxides damage cellular membranes with subsequent release of inflammatory mediators, including TNF-α. Inflammation ensues, which stimulates the fibrogenic cascade with expansion of the extracellular matrix, leading to fibrosis. The inflammatory response may also be stimulated by Kupffer cells and/or bacterial endotoxin in some cases. The actual interplay between all of these factors may differ, depending on the inciting condition for NASH. Gastroenterology 2001 121, 710-723DOI: (10.1053/gast.2001.27126) Copyright © 2001 American Gastroenterological Association Terms and Conditions